ADAMTS13 and thrombotic thrombocytopenic purpura: During biochemical surveillance on the TTP Pathway, 31% of patients were preemptively treated with rituximab due to declining ADAMTS13 activity with the intent to prevent TTP relapse, no patients were treated with preemptive rituximab before the 90 day analysis period.